FUNDING NOW BOSTON
Navigating the Path to Financing
The path to funding is never easy for an early-stage life science company. The 2023 outlook on investments indicates that venture capitalists will continue to have a high bar for investing in new companies. So, when you gain traction from potential investors, having your ducks in a row is critical to setting yourself up for a successful engagement. Understanding which key milestones investors seek can help you know when to engage and how to prepare in advance. Additionally, understanding which audited financial statements and GAAP accounting records are needed will prevent delays in the due diligence process. Implementing these practices early on can help you with your current round of funding and be prepared for future rounds by knowing how much you need to get there and identifying issues that could create problems later on.
Learn from investors on what sets companies apart in 2023 and from audit professionals on how to put your best foot forward when seeking funding.